Pharmacologic augmentation of high-density lipoproteins: Mechanisms of currently available and emerging therapies

Current Opinion in Cardiology

Volumn 20, Issue 4, 2005, Pages 307-312

  Meyers, C Daniel ^a   Kashyap, Moti L ^a,b  

^a VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Apolipoprotein AI; Atherosclerosis; Drugs; High density lipoproteins; Reverse cholesterol transport

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; 2,4 THIAZOLIDINEDIONE DERIVATIVE; APOLIPOPROTEIN A1; ATORVASTATIN; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; ETC 216; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; NICOTINIC ACID; PEPTIDE D 4F; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHOLIPID; PIOGLITAZONE; ROSIGLITAZONE; SIMVASTATIN; STATINE DERIVATIVE; SYNTHETIC PEPTIDE; TORCETRAPIB; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; DRUG MECHANISM; DYSLIPIDEMIA; HEART PROTECTION; HUMAN; LIPOPROTEIN METABOLISM; LIPOPROTEIN SYNTHESIS; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTILIPEMIC AGENTS; APOLIPOPROTEIN A-I; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CARRIER PROTEINS; CHOLESTEROL ESTER TRANSFER PROTEINS; CLOFIBRIC ACID; GLYCOPROTEINS; HUMANS; LIPOPROTEINS, HDL; SULFHYDRYL COMPOUNDS; THIAZOLIDINEDIONES;

EID: 21244496784     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hco.0000167718.30076.24     Document Type: Review

References (52)

1. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7-22.
2. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986; 8:1245-1255.
3. Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 2001; 285:1585-1591.
4. Whitney EJ, Krasuski RA, Personius BE, et al. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann Intern Med 2005; 142:95-104. A randomized trial (n = 143) showing that combined gemfibrozil, niacin, and cholestyramine raised HDL-C (by 36%), decreased angiographic coronary atherosclerosis, and prevented clinical cardiovascular events compared to placebo.
5. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323:1289-1298.
6. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345:1583-1592.
7. Wierzbicki AS. Have we forgotten the pivotal role of high-density lipoprotein cholesterol in atherosclerosis prevention? Curr Med Res Opin 2005; 21: 299-306.
8. Linsel-Nitschke P, Tall AR. HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat Rev Drug Discov 2005; 4:193-205.
9. Meyers CD, Kashyap ML. Pharmacologic elevation of high-density lipoproteins: recent insights on mechanism of action and atherosclerosis protection. Curr Opin Cardiol 2004; 19:366-373.
10. Sakai T, Kamanna VS, Kashyap ML. Niacin, but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol. Arterioscler Thromb Vasc Biol 2001; 21:1783-1789.
11. Asztalos BF. High-density lipoprotein metabolism and progression of atherosclerosis: new insights from the HDL Atherosclerosis Treatment Study. Curr Opin Cardiol 2004; 19:385-391.
12. Brewer HB Jr, Remaley AT, Neufeld EB, et al. Regulation of plasma high-density lipoprotein levels by the ABCA1 transporter and the emerging role of high-density lipoprotein in the treatment of cardiovascular disease. Arterioscler Thromb Vasc Biol 2004; 24:1755-1760.
13. Calabresi L, Gomaraschi M, Franceschini G. Endothelial protection by high-density lipoproteins: from bench to bedside. Arterioscler Thromb Vasc Biol 2003; 23:1724-1731.
14. Mackness MI, Mackness B, Durrington PN. Paraoxonase and coronary heart disease. Atheroscler Suppl 2002; 3:49-55.
15. Karasawa K, Harada A, Satoh N, et al. Plasma platelet activating factor-acetylhydrolase (PAF-AH). Prog Lipid Res 2003; 42:93-114.
16. Von Eckardstein A, Hersberger M, Rohrer L. Current understanding of the metabolism and biological actions of HDL. Curr Opin Clin Nutr Metab Care 2005; 8:147-152.
17. Canner PL, Furberg CD, Terrin ML, McGovern ME. Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol 2005; 95:254-257.
18. Taylor AJ, Sullenberger LE, Lee HJ, et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004; 110:3512-3517.
19. Meyers CD, Kamanna VS, Kashyap ML. Niacin therapy in atherosclerosis. Curr Opin Lipidol 2004; 15:659-665. A thorough review of the basic mechanisms, clinical effects, and cardiovascular outcomes studies of niacin.
20. Ganji SH, Tavintharan S, Zhu D, et al. Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells. J Lipid Res 2004; 45:1835-1845. Important research identifying diacylglycerol acyltransferase 2 as a major target for niacin's effects on hepatic triglyceride production.
21. Rubic T, Trottmann M, Lorenz RL. Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin. Biochem Pharmacol 2004; 67:411-419. Intriguing research demonstrating that niacin increases ABCA1 and CD36 mRNA expression in macrophages, resulting in increased reverse cholesterol transport.
22. Ikewaki K, Tohyama J, Nakata Y, et al. Fenofibrate effectively reduces remnants, and small dense LDL, and increases HDL particle number in hypertriglyceridemic men - a nuclear magnetic resonance study. J Atheroscler Thromb 2004; 11:278-285.
23. Tonelli M, Collins D, Robins S, et al. Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency. Kidney Int 2004; 66:1123-1130.
24. Arakawa R, Tamehiro N, Nishimaki-Mogami T, et al. Fenofibric acid, an active form of fenofibrate, increases apolipoprotein A-I-mediated high-density lipoprotein biogenesis by enhancing transcription of ATP-binding cassette transporter A1 gene in a liver X receptor-dependent manner. Arterioscler Thromb Vasc Biol 2005, March 24 [Epub ahead of print].
25. Duez H, Lefebvre B, Poulain P, et al. Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation. Arterioscler Thromb Vasc Biol 2005; 25:585-591.
26. Olsson AG, Schwartz GG, Szarek M, et al. High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. Eur Heart J 2005; 26:890-896. Interestingly, baseline HDL-C (but not LDL-C) predicted recurrent events in this group of patients with acute coronary syndrome, and cardiovascular benefits of atorvastatin therapy did not correlate with degree of LDL-C lowering.
27. Qin S, Koga T, Ganji SH, et al. Rosuvastatin stimulates apolipoprotein-AI synthesis but not HDL catabolism by human hepatoblastoma cells (Hep G2). Arterioscler Thromb Vasc Biol 2003; 23;55a.
28. Maejima T, Yamazaki H, Aoki T, et al. Effect of pitavastatin on apolipoprotein A-I production in HepG2 cell. Biochem Biophys Res Commun 2004; 324:835-839.
29. Mauger JF, Couture P, Paradis ME, Lamarche B. Comparison of the impact of atorvastatin and simvastatin on apoA-I kinetics in men. Atherosclerosis 2005; 178:157-163. This is the first demonstration that a statin (simvastatin) increases apoAI concentrations in vivo through increased rates of production, confirming prior in-vitro data.
30. Ota K, Suehiro T, Arii K, et al. Effect of pitavastatin on transactivation of human serum paraoxonase 1 gene. Metabolism 2005; 54:142-150.
31. Harangi M, Seres I, Varga Z, et al. Atorvastatin effect on high-density lipoprotein-associated paraoxonase activity and oxidative DNA damage. Eur J Clin Pharmacol 2004; 60:685-691. This is an important in-vivo confirmation that statin's effect on paroxonase gene transcription may be of physiological relevance.
32. Chiquette E, Ramirez G, Defronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004; 164:2097-2104.
33. Gegick CG, Altheimer MD. Thiazolidinediones: comparison of long-term effects on glycemic control and cardiovascular risk factors. Curr Med Res Opin 2004; 20:919-930.
34. Parhofer KG, Otto C, Geiss HC, et al. Effect of pioglitazone on lipids in well controlled patients with diabetes mellitus type 2 - results of a pilot study. Exp Clin Endocrinol Diabetes 2005; 113:49-52.
35. Qin S, Liu T, Kamanna VS, Kashyap ML. Pioglitazone stimulates apolipoprotein AI production without affecting HDL protein and cholesterol ester removal in HepG2 cells. Circulation 2004; 110:111-37. This research suggests that the HDL-C-raising effect of pioglitazone is based on its ability to act as a partial agonist of PPARα.
36. Moon YS, Kashyap ML. Pharmacologic treatment of type 2 diabetic dyslipidemia. Pharmacotherapy 2004; 24:1692-1713. Comprehensive review of the significance, pathophysiology, and treatment of diabetic dyslipidemia (high triglycerides, low HDL-C, and small dense LDL).
37. Zhang B, Fan P, Shimoji E, et al. Inhibition of cholesteryl ester transfer protein activity by JTT-705 increases apolipoprotein E-containing high-density lipoprotein and favorably affects the function and enzyme composition of high-density lipoprotein in rabbits. Arterioscler Thromb Vasc Biol 2004; 24: 1910-1915.
38. Lloyd DB, Lira ME, Wood LS, et al. Cholesteryl ester transfer protein variants have differential stability but uniform inhibition by torcetrapib. J Biol Chem 2005.
39. Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004; 350: 1505-1515. Impressive clinical data showing the safety and efficacy (up to 106% elevation of HDL-C) of torcetrapib.
40. Brousseau ME, Diffenderfer MR, Millar JS, et al. Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arterioscler Thromb Vasc Biol 2005; 25:1057-1064. In this kinetic study, torcetrapib significantly increased the HDL apoAI pool primarily by decreased the fractional catabolic rate of apoAI. This suggests that CE-enriched HDL particles are resistant to holoparticle catabolism. Torcetrapib had no effect on the production rate of apoAI.
41. van der Steeg WA, Kuivenhoven JA, Klerkx AH, et al. Role of CETP inhibitors in the treatment of dyslipidemia. Curr Opin Lipidol 2004; 15:631-636.
42. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003; 290:2292-2300.
43. milano-phospholipid complexes restores endothelial function, reduces aortic cholesterol content, and reduces platelet aggregability in hypercholesterolemic apoE null mice. Neither apoAImilano nor phospholipid alone showed beneficial effects - important controls that were not included in Nissen's human study.
44. Marchesi M, Booth EA, Davis T, et al. Apolipoprotein A-IMilano and 1-palmitoyl-2-oleoyl phosphatidylcholine complex (ETC-216) protects the in vivo rabbit heart from regional ischemia-reperfusion injury. J Pharmacol Exp Ther 2004; 311:1023-1031.
45. Epand RM, Epand RF, Sayer BG, et al. Two homologous apolipoprotein AI mimetic peptides. Relationship between membrane interactions and biological activity. J Biol Chem 2004; 279:51404-51414.
46. Epand RM, Epand RF, Sayer BG, et al. An apolipoprotein AI mimetic peptide: membrane interactions and the role of cholesterol. Biochemistry 2004; 43:5073-5083.
47. Van Lenten BJ, Wagner AC, Navab M, et al. D-4F, an apolipoprotein A-I mimetic peptide, inhibits the inflammatory response induced by influenza A infection of human type II pneumocytes. Circulation 2004; 110:3252-3258.
48. Navab M, Anantharamaiah GM, Reddy ST, et al. Oral D-4F causes formation of pre-beta high-density upoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation 2004; 109:3215-3220.
49. Li X, Chyu KY, Neto JR, et al. Differential effects of apolipoprotein A-I-mimetic peptide on evolving and established atherosclerosis in apolipoprotein E-null mice. Circulation 2004; 110:1701-1705. Oral or intraperitoneal administration of D-4F significantly reduces atherosclerosis in graft vein (but not native vessel) lesions in apoE null mice. Additional studies are needed to define the future role of apoAI mimetic peptides in human atherosclerotic lesions.
50. Hajj Hassan H, Blain S, Boucher B, et al. Structural modification of plasma HDL by phospholipids promotes efficient ABCA1-mediated cholesterol release. J Lipid Res 2005, January 16 [Epub ahead of print].
51. Burgess JW, Boucher J, Neville TA, et al. Phosphatidylinositol promotes cholesterol transport and excretion. J Lipid Res 2003; 44:1355-1363.
52. Burgess JW, Neville TA, Rouillard P, et al. Phosphatidylinositol increases HDL-C levels in humans. J Lipid Res 2005; 46:350-355. Patients given oral Phosphatidylinositol (5.6 g a day for 2 weeks) experienced an 18% increase in HDL-C with few side effects.